Valuation: Valneva SE

Market Cap 477M 535M 442M 400M 753M 50.53B 762M 5.3B 2.08B 26.56B 2.01B 1.97B 84.64B P/E 2026 *
-5.77x
P/E 2027 * 9.11x
Enterprise Value 611M 686M 566M 512M 964M 64.69B 976M 6.78B 2.66B 34B 2.57B 2.52B 108B EV / Sales 2026 *
4.05x
EV / Sales 2027 * 1.9x
Free-Float
89.26%
Yield 2026 *
-
Yield 2027 * -
1 day-1.75%
1 week-2.52%
Current month-8.78%
1 month-13.35%
3 months+15.95%
6 months-4.67%
Current year-33.51%
1 week 2.36
Extreme 2.365
2.62
1 month 2.36
Extreme 2.365
2.87
Current year 2.03
Extreme 2.033
5.15
1 year 2.03
Extreme 2.033
5.15
3 years 1.73
Extreme 1.726
7.17
5 years 1.73
Extreme 1.726
29.7
10 years 1.73
Extreme 1.726
29.7
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 29/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 20/12/2023
Director/Board Member 75 07/03/2013
Chairman 65 20/12/2023
Date Insider Type Main position Quantity % Market Cap. Importance
27/01/26 Sell

Chief Technology Officer

11,800 0.0069%
26/01/26 Sell

Chief Financial Officer

11,800 0.0069%
19/01/26 Exercice

Chief Technology Officer

82,899 0.0482%
Change 5-day change 1-year change 3-year change Capi.($)
-1.75%-2.52%-40.95%-52.42% 536M
-0.21%-6.36%+49.00%+74.13% 66.34B
-0.22%+6.53%+11.68%+90.35% 52.92B
+0.82%+5.41%+8.05%+74.45% 54.82B
+2.99%+4.68%+25.43%+49.30% 44.09B
+0.46%+9.91%+22.35%+128.95% 43.72B
-0.95%+0.49%+263.54%+959.44% 42.13B
+0.10%+9.96%+17.15%+59.33% 33.96B
-1.30%-3.61%+37.37%+7.16% 26.17B
+0.69%+5.60%+36.60%+26.39% 23.37B
Average +0.01%+4.24%+43.02%+141.71% 38.8B
Weighted average by Cap. +0.24%+4.66%+51.30%+167.00%

Financials

2026 *2027 *
Net sales 151M 169M 140M 127M 238M 15.99B 241M 1.68B 658M 8.41B 636M 622M 26.78B 283M 318M 262M 237M 447M 30.01B 453M 3.15B 1.23B 15.77B 1.19B 1.17B 50.26B
Net income -81.11M -91.03M -75.1M -67.96M -128M -8.59B -130M -900M -353M -4.52B -341M -334M -14.39B 53.07M 59.56M 49.14M 44.47M 83.78M 5.62B 84.77M 589M 231M 2.95B 223M 219M 9.41B
Net Debt 134M 150M 124M 112M 211M 14.16B 214M 1.48B 582M 7.44B 563M 551M 23.72B 62.48M 70.11M 57.84M 52.35M 98.62M 6.62B 99.79M 694M 272M 3.48B 263M 258M 11.08B
Projected Income Statement - Annual - Valneva SE
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
620
Date Price Change Volume
21/10/26 €2.472 -1.75% 370,104
20/10/26 €2.516 +3.88% 720,831
19/10/26 €2.422 -3.85% 692,354
16/10/26 €2.519 -2.55% 276,991
15/10/26 €2.585 +1.93% 233,019
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Valneva SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.516EUR
Average target price
6.193EUR
Spread / Average Target
+146.14%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Valneva SE